ProfileGDS5678 / 1456228_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 47% 30% 30% 30% 28% 28% 50% 65% 30% 29% 30% 27% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6969829
GSM967853U87-EV human glioblastoma xenograft - Control 23.1036347
GSM967854U87-EV human glioblastoma xenograft - Control 32.681430
GSM967855U87-EV human glioblastoma xenograft - Control 42.6290630
GSM967856U87-EV human glioblastoma xenograft - Control 52.6294330
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7223628
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6832928
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1897550
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8922765
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6649630
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6409729
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6486730
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6258827
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6678330